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Abstract: Three docetaxel (DX) lipid conjugates: 2′-lauroyl-docetaxel (C12-DX), 2′-stearoyl-
docetaxel (C18-DX), and 2′-behenoyl-docetaxel (C22-DX) were synthesized to enhance drug 
loading, entrapment, and retention in liquid oil-filled lipid nanoparticles (NPs). The three 
conjugates showed ten-fold higher solubility in the liquid oil phase Miglyol 808 than DX. 
To further increase the drug entrapment efficiency in NPs, orthogonal design was performed. 
The optimized formulation was composed of Miglyol 808, Brij 78, and Vitamin E tocopheryl 
polyethylene glycol succinate (TPGS). The conjugates were successfully entrapped in the 
reduced-surfactant NPs with entrapment efficiencies of about 50%–60% as measured by gel 
permeation chromatography (GPC) at a final concentration of 0.5 mg/mL. All three conjugates 
showed 45% initial burst release in 100% mouse plasma. Whereas C12-DX showed another 
40% release over the next 8 hours, C18-DX and C22-DX in NPs showed no additional release 
after the initial burst of drug. All conjugates showed significantly lower cytotoxicity than DX 
in human DU-145 prostate cancer cells. The half maximal inhibitory concentration values 
(IC50) of free conjugates and conjugate NPs were comparable except for C22-DX, which was 
nontoxic in the tested concentration range and showed only vehicle toxicity when entrapped 
in NPs. In vivo, the total area under the curve (AUC0-∞) values of all DX conjugate NPs were 
significantly greater than that of Taxotere, demonstrating prolonged retention of drug in the 
blood. The AUC0-∞ value of DX in Taxotere was 8.3-fold, 358.0-fold, and 454.5-fold lower 
than that of NP-formulated C12-DX, C18-DX, and C22-DX, respectively. The results of these 
studies strongly support the idea that the physical/chemical properties of DX conjugates may 
be fine-tuned to influence the affinity and retention of DX in oil-filled lipid NPs, which leads 
to very different pharmacokinetic profiles and blood exposure of an otherwise potent chemo-
therapeutic agent. These studies and methodologies may allow for improved and more potent 
nanoparticle-based formulations.
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Introduction
Docetaxel (DX) is a potent anticancer drug used to treat various cancers including 
metastatic androgen-independent prostate cancer, breast cancer, and advanced non-
small cell lung cancer.1–3 DX inhibits cell growth by binding to microtubules, stabilizing 
them, and preventing their depolymerization.4 Currently, Taxotere® (Sanofi–Aventis, 
Bridgewater NJ) is the only commercial formulation of DX on the market. The formu-
lation contains a solvent system of polysorbate 80 and ethanol. Side-effects related to 
these excipients have been reported, including hypersensitivity and fluid retention.5–9 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Great effort has been made to develop safer formulations 
to effectively deliver DX, including micelles, liposomes, 
nanoemulsions, solid lipid nanoparticles, nanocapsules, and 
polymeric nanoparticles.10–15 Given the hydrophobic property 
of DX, lipid-based NPs, especially liquid oil-filled NPs, serve 
as a viable alternative delivery system. Lipid-based NPs have 
the advantages of low toxicity, capability for controlled drug 
release, and the potential to penetrate the leaky vasculature 
of tumors.
The enhanced permeability and retention (EPR) effect is 
the major mechanism for passive targeting of anticancer drug 
formulations to accumulate in the tumor site. To ensure that 
the NPs take advantage of the EPR effect, the NPs need to 
maintain two aspects of stability in vivo: long circulation of 
delivery vehicles and long retention of anticancer agents in 
the NPs. The importance of long circulation of NPs has been 
widely recognized and extensively demonstrated for decades. 
Various polyethylene glycol (PEG)-coated nano-formula-
tions have shown prolonged circulation time in vivo.16–19 On 
the other hand, the enhancement of drug retention in long 
circulating NPs increases drug uptake and accumulation 
in the tumor tissue. To study the retention of drugs in the 
NPs, many in vitro release studies have been conducted in 
aqueous buffers (eg, phosphate buffered saline [PBS]) and 
are expected to predict the in vivo retention behaviors of 
the nano-formulation. However, the correlation between the 
in vitro release in PBS and in vivo release behavior is often 
poor, especially when the entrapped drug has extremely low 
aqueous solubility and/or high protein binding affinity. Given 
that DX has poor water solubility and high protein binding,20 
we developed a more predictive “ex vivo” release method to 
better mimic the in vivo environment with the goal to achieve 
better correlation with the pharmacokinetic profiles.
Previously, we developed liquid-oil filled Brij 78, 
Vitamin E TPGS and Miglyol (BTM) 808 NPs to deliver DX. 
However, despite the desirable formulation properties (eg, 
monodisperse particle size, apparent drug entrapment effi-
ciency, etc), DX was found to be rapidly released in mouse 
plasma in vitro and nearly superimposable pharmacokinetic 
profiles with Taxotere were observed (unpublished data). 
Despite the fact that DX is a poorly water-soluble drug, 
which favors the oil phase over the aqueous phase during 
preparation, DX has appreciable solubility in aqueous solu-
tions and is highly protein bound. Moreover, the affinity of 
DX with the oil core is not high enough to prevent its rapid 
diffusion from the oil core to an aqueous phase comprised 
of 100% plasma. These factors led to the poor retention of 
DX in the BTM 808 NPs in plasma and in vivo.
The objective of this study was to improve the affinity 
and retention of DX in the NPs to thereby achieve prolonged 
in vivo blood exposure. To this end, we synthesized three 
lipid-DX prodrugs with different fatty acid chain lengths. The 
chain lengths (12, 18, and 22) were chosen to be compatible 
with the liquid oil core, Miglyol 808, which is composed 
of caprylic acid triglycerides. By utilizing the new release 
method to investigate the in vitro release of the conjugates 
from these NPs, a correlation between the in vitro release 
and in vivo pharmacokinetics was achieved. The superior 
pharmacokinetic profiles of the three conjugates in NPs 
compared to Taxotere makes them promising candidates for 
preclinical anticancer efficacy studies.
Materials and methods
Materials and animals
Docetaxel, paclitaxel (PX), lauroyl chloride (98%), stearoyl chlo-
ride (97%), behenoyl chloride (.99%) and 4-(dimethylamino)
pyridine (DMAP) were purchased from Sigma-Aldrich (St 
Louis, MO). Miglyol 808 was obtained from Sasol (Witten, 
  Germany). Polyoxyl 20-stearyl ether (Brij 78) was obtained 
from Uniqema (Wilmington, DE). D-alpha-tocopheryl 
polyethylene glycol succinate (Vitamin E TPGS) was 
purchased from Eastman Chemicals (Kingsport, TN). BALB/c 
mouse plasma was purchased from Innovative Research 
Inc (Novi, MI).   Sepharose CL-4B was purchased from GE 
Healthcare   (Uppsala, Sweden). Hybrid-SPE® cartridge was 
purchased from Sigma-Aldrich Supelco (St Louis, MO).
The human prostate cancer cell line, DU-145, was 
obtained from the American Type Collection   (Manassas, 
VA) and was maintained in RPMI-1640 medium with 10% 
fetal bovine serum (FBS). Male athymic nude (nu/nu) 
mice, 4–5 weeks old, were obtained from the University of 
North Carolina, Division of Laboratory Animal Medicine 
(Chapel Hill, NC) and housed in a pathogen-free room. All 
experiments involving mice were conducted according to an 
approved animal protocol by the University of North Carolina 
Institutional Animal Care and Use Committee.
synthesis
general procedure for the synthesis  
of 2′-lauroyl-docetaxel (1, c12-DX)21
A flame-dried round-bottom flask was charged with DX 
(0.2 g, 2.48 × 10-4 mol, 1 equiv) and 4-(dimethylamino)pyri-
dine (DMAP) (0.06 g, 4.95 × 10-4 mol, 2 equiv) in dry CH2Cl2 
(8 mL) under argon. The solution was stirred for 10 minutes 
at 0°C. Lauroyl chloride (57.2 µl, 2.48 × 10-4 mol, 1 equiv) 
was added, and the reaction mixture was stirred for 6 hours International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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at 0°C. The reaction was monitored by thin layer chroma-
tography (TLC) (CH2Cl2: MeOH 9:1 v/v; Rf = 0.7) for 
completion. After completion, the solvent was removed by 
rotary evaporation in vacuo and the crude product was dis-
solved in diethyl ether (50 mL) and washed with 5% HCl 
(3 × 40 mL), and finally with brine (40 mL) to remove the 
salt byproducts. The organic phase was dried over anhy-
drous sodium sulfate, and the solvent was evaporated in 
vacuo. The product was purified by silica-packed column 
chromatography (9:1 CH2Cl2:MeOH) to give the desired 
DX derivative as a white solid (0.21 g, yield 85%). 1H NMR 
(400 MHz, CDCl3): δ (ppm) = 1.12 (t, 3H, -CH3(CH2)10), 
1.23 (s, 6H, -H16,17), 1.34 (s, 9H, -H7′–9′), 1.72 (s, 3H, -H19), 
1.75 (m, 14H, -(CH2)7CH2CH3), 1.81 (m, 2H, -CH2CH2C1″), 
1.84 (s, 3H, -H18), 1.87 (m, 2H, -H14), 2.26 (d, 2H, -CH2C1″), 
2.36 (s, 3H, -H22), 2.67 (m, 1H, -H3), 3.43 (s, 1H, -H7), 
3.9 (d, 1H, -H4), 4.17 (d, 1H, -H6), 4.24 (m, 1H, -H5), 4.3 
(d, 1H, -H20), 4.61 (s, 1H, –H10), 4.93 (d, 1H, -H13), 5.21 
(d, 1H, -H10), 5.67 (d, 1H, -H2), 6.21 (t, 1H, -H2′), 7.31 
(m, 1H, -H3′), 7.36–7.61 (m, 8H, -Ar-H26–28 and Ar-H30–35), 
8.1 (d, 2H, -Ar-H25,29).  13C NMR (100 MHz, CD3OD): 
δ (ppm) = 9.9 (-C19), 14.4 (-CH3(CH2)10), 20.6 (-C18), 22.5 
(-C22), 24.8 (-(CH2)9CH2CH3), 26.44 (-C16,17), 28.2 (-C7′–9′), 
31.9 (- (CH2)8C1”), 34.4 (–C6,14), 43.1 (–C15), 46.4 (–C3), 
56.4 (-C3′), 57.6 (-C8), 72 (-C13), 72.4 (-C7), 74.5 (-C2), 
74.8 (-C10), 76.6 (-C20), 78.8 (-C6′), 80.2 (-C1), 81.1(-C4), 
84.1 (–C5), 126. 7 (–C31,33,35), 128 (-C32,34), 128.7 (-C26,28), 
130.2 (-C24,25,29), 133.7 (-C27), 135.9 (-C11), 138.5 (-C12), 
155.3 (-C5′), 167.1, 167 (-C23), 172.7 (-C21), 174 (-C1), 
177.8 (-C1″), 211.6 (-C9).
general procedure for the synthesis of 2′-stearoyl-
docetaxel (2, c18-DX)
2′-stearoyl-docetaxel was synthesized following the same pro-
cedure outlined above for 2′-lauroyl-docetaxel using stearoyl 
chloride to give the final conjugate as a white solid (0.17 g, 
yield 65%). 1H NMR (400 MHz, CDCl3): δ (ppm) = 0.8 (t, 
3H, -CH3(CH2)16), 1.05 (s, 6H, –H16,17), 1.14 (s, 9H, -H7′–9′), 
1.16 (s, 3H, -H19), 1.26 (m, 14H, - (CH2)13CH2CH3), 1.45 
(m, 2H, -CH2CH2C1″), 1.68 (s, 3H, -H18), 1.88 (m, 2H, -H14), 
2.25 (d, 2H, -CH2C1″), 2.37 (s, 3H, -H22), 2.38 (m, 1H, -H3), 
3.43 (s, 1H, -H7), 3.85 (d, 1H, -H4), 4.12 (d, 1H, -H6), 
4.24 (m, 1H, –H5), 4.3 (d, 1H, -H20), 4.88 (d, 1H, -H13), 
5.14 (s, 1H, -H10), 5.3 (d, 1H, -H10), 5.61 (d, 1H, -H2), 6.2 
(t, 1H, -H2′), 7.2 (m, 1H, -H3′), 7.25–7.53 (m, 8H, -Ar-H26–28 
and Ar-H30–35), 8.05 (d, 2H, -Ar-H25,29). 13C NMR (100 MHz, 
CD3OD): δ (ppm) = 8.9 (–C19), 13.2 (-CH3(CH2)16), 
19.9 (-C18), 21.6 (-C22), 23.7 (-(CH2)15CH2CH3), 25.3 (-C16,17), 
27.1 (–C7′–9′), 30.9 (-(CH2)14C1″), 32.7 (-C6,14), 42.1 (–C15), 
45.4 (-C3), 56.4 (-C3′), 57.6 (-C8), 70.8 (-C13), 73.1 (-C7), 
73.5 (-C2), 74 (–C10), 77.9 (-C20), 79.4 (-C6′), 79.9 (-C1), 
83.2 (-C4), 84.1 (-C5), 125.3 (-C31,33,35), 127.1 (-C32,34), 127.8 
(-C26,28), 129.2 (-C24,25,29), 132.6 (–C27), 134.5 (-C11), 138.2 
(-C12), 154.1 (-C5′), 166.1 (-C23), 167.2 (–C21), 168.7 (-C1), 
171.8 (-C1″), 210.6 (-C9).
general procedure for the synthesis  
of 2′-behenoyl-docetaxel (3, c22-DX)
2′-behenoyl-docetaxel was synthesized following the 
same procedure outlined above for 2′-lauroyl-docetaxel 
using behenoyl chloride to give the final conjugate as 
a white solid (0.26 g, yield 95%).  1H NMR (400 MHz, 
CDCl3): δ (ppm) = 0.81 (t, 3H, -CH3(CH2)20), 1.05 
(s, 6H, -H16,17), 1.14 (s, 9H, -H7′–9′), 1.16 (s, 3H, -H19), 1.23 
(m, 36H, -(CH2)18CH2CH3), 1.26 (m, 2H, -CH2CH2C1″), 1.45 
(s, 3H, -H18), 1.62 (m, 2H, -H14), 1.67 (d, 2H, -CH2C1″), 
1.9 (s, 3H, -H22), 2.26 (m, 1H, -H3), 2.4 (s, 1H, -H7), 
3.86 (d, 1H, -H4), 4.12 (d, 1H, -H6), 4.23 (m, 1H, -H5), 
4.26 (d, 1H, -H20), 4.61 (s, 1H, -H10), 4.9 (d, 1H, -H13), 
5.14 (d, 1H, -H10), 5.62 (d, 1H, -H2), 6.2 (t, 1H, -H2′), 7.2 
(m, 1H, -H3′), 7.22–7.53 (m, 8H, -Ar-H26–28 and Ar-H30–35), 
8.05 (d, 2H, -Ar-H25,29).  13C NMR (100 MHz, CD3OD): 
δ (ppm) = 8.9 (-C19), 13.2 (-CH3(CH2)20), 19.9 (-C18), 
21.6 (-C22), 23.7 (-(CH2)19CH2CH3), 25.3 (-C16,17), 27.1 
(-C7′–9′), 30.9 (- (CH2)18C1″), 32.7 (-C6,14), 42.1 (-C15), 45.4 
(–C3), 56.5(-C3′), 57.2 (-C8), 70.8 (-C13), 73.1 (-C7), 73.5 
(-C2), 74.0 (-C10), 76.3 (-C20), 77.9 (-C6′), 79.9 (-C1), 
83.2(-C4), 84.1 (-C5), 125.3 (-C31,33,35), 127.1 (-C32,34), 127.8 
(-C26,28), 129.2 (-C24,25,29), 132.6 (-C27), 134.5 (-C11), 138.2 
(-C12), 154.2 (-C5′), 166.1, 167.2 (-C23), 168.4 (-C21), 171.8 
(-C1), 177.8 (-C1″), 210.6 (-C9).
characterization of DX and DX 
conjugates
Mass spectrometry
Electrospray ionization (ESI) coupled with direct injection 
was employed to determine the m/z of the final synthetic 
conjugate products by Thermo Scientific TSQ Quantum 
Access (Waltham, MA) with positive ionization. The mass 
of the observed molecular ions were m/z = 1012.6, 1096.7, 
and 1152.8, which clearly corresponded to the Na+ adducts 
of C12-DX, C18-DX, and C22-DX respectively.
high performance liquid chromatography (hPLc)
The DX conjugate concentrations were quantified by HPLC 
using a Finnigan Surveyor HPLC system (Thermo Finnigan, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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San Jose, CA) with a Photodiode Array (PDA) plus   detector, 
autosampler, and LC pump plus with a Inertsil® ODS-3 
  column (4 µm, 4.6 × 150 mm, [GL Sciences, Torrance, 
CA]) at 25°C. Chromatographic separation was achieved by 
gradient elution using mobile phase 2-propanol, acetonitrile 
(ACN), and water (5: 55: 40 v/v/v). The flow rate was 
1.0 mL/minute and the total run time was 25 minutes for 
each 25 µL injection. The wavelength was 230 nm.
The DX concentration was quantified by LC/MS/
MS using a Finnigan Surveyor Autosampler Plus and 
Finnigan   Surveyor MS Pump Plus (Thermo Finnigan). 
  Chromatographic separations were achieved using a 
  SunFire™ C18 column (2.1 × 30 mm, 3.5 µm particle size, 
[Waters, Milford, MA]) at 25°C. The mobile phase consisted 
of 0.1% formic acid in water and methanol using gradient 
separation. The flow rate was 0.5 mL/minute and the total 
run time was 8 minutes for each 25 µL injection. Mass spec-
trometric analysis was performed using a Thermo Scientific 
TSQ Quantum Access with positive ionization. The capillary 
temperature was set up to 390°C, and the spray voltage was 
4000V . For DX analysis, m/z 830.0 → 549.0 was monitored 
with PX (m/z 876.3 → 308.0) as an internal standard.
evaluation of DX conjugate solubility  
in Miglyol 808 and mouse plasma
Approximately 5 mg of DX or 50 mg of each DX conjugate 
was added to individual vials containing 50 µL of Miglyol 
808. For the evaluation of DX and DX conjugate solubility 
in mouse plasma, around 1 mg of each DX conjugate or 
DX was added to a vial containing 1 mL of BALB/c mouse 
plasma. The mixtures were stirred at room temperature for 
24 hours. The samples were then centrifuged for 1 hour at 
14,000 rpm to remove undissolved drugs. After centrifuga-
tion, the saturated supernatant was diluted with ACN and 
analyzed by HPLC.
Preparation and characterization  
of BTM NPs
Preparation of BTM NPs containing DX conjugates
DX conjugates containing NPs were prepared using a warm 
oil-in-water (o/w) microemulsion precursor method previ-
ously developed in our laboratory.22 Briefly, defined amounts 
of Miglyol 808 and surfactants (Brij 78 and   Vitamin E 
TPGS) were accurately weighed into glass vials and heated 
to 50°C–60°C. Drugs dissolved in ACN were added and 
the organic solvent was removed by nitrogen flow. One 
  milliliter of pre-heated 10% lactose in water was added into 
the   mixture of melted oil, surfactants and drugs. The mixture 
was stirred for 20 minutes at 50°C–60°C then cooled to room 
temperature. Orthogonal design was performed to optimize 
nanoparticles with desirable properties, including particle 
size and drug entrapment efficiency.
For in vivo studies, NPs were concentrated and   PEGylated. 
The formulation was concentrated four-fold by adding four-
fold less 10% lactose continuous phase while keeping the 
other components of the formulation unchanged. The NPs 
were PEGylated by adding 8% Brij 700 (w/w Brij 700/
Miglyol 808) during the preparation.
characterization of BTM NPs  
containing DX conjugates
Particle size and zeta potential
Particle size and size distribution of NPs were determined 
using N5 Submicron Particle Size Analyzer (Beckman 
Coulter, Brea, CA). Five microliters of NPs was diluted with 
1 mL of water to reach the intensity required by the instrument. 
Particle size was determined at 90° light scattering at 25°C. 
The zeta potential of NPs was determined using the Zetasizer 
Nano Z (Malvern Instruments, Southborough, MA).
Drug entrapment efficiency
Drug entrapment efficiency was determined by GPC. DX 
conjugate NPs were separated from the free drugs using 
a 15 cm Sepharose CL-4B GPC column (GE Healthcare, 
Pittsburg, PA). NPs were eluted by PBS in fraction 5–8 
(1 mL/fraction, confirmed by dynamic light scattering 
intensity). Each fraction was evaporated to dryness in 
vacuo, resuspended in 1 mL ACN, and analyzed by HPLC 
to determine the concentration of DX conjugate in each 
fraction. The percentage of drug entrapment efficiency was 
defined as 100% × the ratio of the weight of drug detected 
in fraction 5–8 to the total drug weight detected.
Drug release in mouse plasma
In vitro release studies were performed in 100% plasma from 
BALB/c mice. Briefly, 100 µL of purified DX conjugate NPs 
were spiked into 2 mL of mouse plasma. The release mixture 
was incubated at 37°C in a water bath shaker. At designated 
time points from 0–8 hours, two aliquots of release mixture 
were removed. One aliquot (100 µL) was used to determine 
the total drug concentration by solid phase extraction (SPE) 
using Hybrid-SPE precipitate method. Briefly, one volume of 
release mixture was mixed with three volumes of 2% formic 
acid in ACN. Following vortex and centrifugation, the super-
natant was applied to a Hybrid-SPE cartridge. The eluate was 
collected for HPLC analysis. Another aliquot (100 µL) was International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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used to determine the drug remaining in the NPs using the 
method described previously. The percentage of  DX released 
at any time point was calculated as 100% × [(total drug 
detected – drug remaining in the NPs)/total drug detected].
evaluation of in vitro cytotoxicity
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was utilized to assess cytotoxicity of 
free DX conjugates and the DX conjugate NPs. Serial dilu-
tions of free drugs or drug containing NPs were added to the 
DU-145 cells and incubated for 48 hours. The cells were then 
incubated with MTT solution and solubilized by dimethyl 
sulfoxide (DMSO). The absorbance was measured using 
the Synergy 2 Multi-Detection Microplate Reader (BioTek 
Instruments, Winooski, VT) at 570 nm, and the concentra-
tion of drug that inhibited cell survival by 50% (IC50) was 
determined from cell survival plots.
In vitro esterase digestion
The esterase digestion study was performed in fresh mouse 
plasma. The 5 mg/mL DX conjugate solutions in DMSO 
were spiked into the plasma to make a final concentration 
of 10 µg/mL. The mixture was incubated at 37°C in a water 
bath shaker. At designated time points, 100 µL of digestion 
mixture was removed. The concentration of DX conjugates 
was determined by Hybrid-SPE precipitate method as 
described above followed by HPLC analysis. The percentage 
of DX conjugate remaining at any time point was calculated 
as 100% × the ratio of remaining drug amount to the total 
drug spiked into this volume of plasma.
In vivo pharmacokinetic studies
Male athymic nude mice were randomly divided into four 
groups. The mice (n = 3/time point) were injected via tail 
vein with test samples (Taxotere, C12-DX NPs, C18-DX NPs, 
and C22-DX NPs), all at a DX dose of 10 mg/kg. At desig-
nated time points from 3 minutes to 24 hours, the mice were 
given an overdose of ketamine (100 mg/kg) and domitor 
(0.5 mg/kg) for deep anesthesia prior to cardiac puncture to 
collect blood and a cervical dislocation was then performed 
to euthanize the mice. For plasma separation, the blood col-
lected in heparin-coated tubes was centrifuged at 12,300 rpm 
for 15 minutes. The obtained plasma was processed with 
Hybrid-SPE   precipitate method as described above. The con-
centrations of DX conjugates in plasma were determined by 
HPLC, and the DX concentrations were quantified by LC-MS. 
  Pharmacokinetic analysis and modeling was performed by 
Winnonlin (v 5.2.1; Pharsight Corp, Mountain View, CA).
statistical analysis
Statistical comparisons were performed using one-way 
analysis of variance (ANOVA) (GraphPad Prism Software 
Inc, La Jolla, CA). Results were considered significant at 
the 95% confidence interval (P , 0.05). Orthogonal experi-
mental design for formulation optimization was performed 
and statistically analyzed using Design Expert® (v 7.1 Trial; 
Stat-Ease, Minneapolis, MN).
Results
synthesis and characterization  
of DX conjugates
The DX-lipid conjugates in these studies were prepared by a 
one-step esterification reaction using acid chloride derivatives 
of various chain length fatty acids (Figure 1). Although there 
are multiple hydroxyl groups in DX molecule, the 2′-OH is 
the most reactive and accessible one, followed by 7-OH.21 
It has been previously reported that the conjugation of fatty 
acids to DX and PX occurs preferentially on 2′-OH.21,23,24 By 
controlling the molar ratio of the fatty acid chloride to DX 
carefully, 2′-mono substituted DX conjugates were obtained 
with minimal formation of 2′,7-di substituted byproducts 
and unreacted DX. In the case of C22-DX, only the 2′-OH 
ester derivative was obtained after washing with 5% HCl 
and brine as determined by thin layer chromatography and 
nuclear magnetic resonance, without further chromatography 
required. The yield for this reaction was as high as 95%.
solubility of DX conjugates  
in Miglyol 808 and mouse plasma
To enhance the drug loading capacity and retention of drug 
in the NPs, DX conjugates were synthesized and investigated 
for their solubility in Miglyol 808 (Table 1). The solubility 
of all three DX conjugates in Miglyol 808 was about 10-fold 
higher than the solubility of DX. The solubility showed no 
chain-length dependency. The chemical composition of 
Miglyol 808 is caprylic acid triglyceride, so DX conjugates 
with a 12–22 carbon chain are more compatible than DX with 
Miglyol 808 due to the similarity of the chemical structure.
Since the in vitro release of DX conjugates from NPs was 
studied in mouse plasma, the solubility of DX conjugates in 
BALB/c mouse plasma was determined and compared as 
well (Figure 2). In contrast to solubility in Miglyol 808, the 
solubility of DX conjugates in plasma showed significant 
chain-length dependency. With an increase in lipid chain, the 
solubility of the conjugate in plasma decreased. The solubility 
of C12-DX (377.0 ± 21.5 µg/mL) was about 10-fold higher International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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than that of C22-DX (34.4 ± 0.6 µg/mL) and 6.5-fold higher 
than that of C18-DX (57.5 ± 2.6 µg/mL). Given the extremely 
low water solubility of the DX conjugates, the solubility of 
the conjugates in plasma was attributed almost entirely to 
their binding with plasma proteins.
Optimization of DX conjugate-containing 
nanoparticles by orthogonal design
The orthogonal design was based on the NP previously 
developed to formulate DX, which was composed of Miglyol 
808 (2.5 mg/mL), Brij 78 (3.7 mg/mL), TPGS (1.2 mg/mL), 
and DX (0.3 mg/mL). In the present study, particle size and 
drug entrapment efficiency were chosen as responses in the 
optimization process. A criterion in the orthogonal design 
strategy was to reduce the total amount of surfactant used in 
the formulation, as it had been previously established that 
increased levels of surfactants in the formulation decreased 
drug entrapment, especially for drugs that have amphipathic 
properties.
Based on the preliminary studies, a 3-level variable 
orthogonal experiment (L-9 33) was designed as shown 
in Table 2. The two responses selected were particle size 
and percent of entrapment efficiency. In this experiment, 
C12-DX was used as a representative DX conjugate. The 
resulting NP compositions based on the optimization using 
C12-DX were applied to other conjugates. Nine batches 
of C12-DX NPs were prepared and characterized. Results 
are also shown in Table 2. Statistical analysis showed that 
temperature as a variable was not significant to the model 
(P . 0.05). The particle size, as a defined model response, 
was not responsive to the variables (P . 0.05). It should be 
noted that the general placebo composition for this formula-
tion was previously optimized.22 Thus, it was anticipated that 
continued optimization with DX conjugates would lead to a 
relatively narrow response range. When the model focused 
on the effect of surfactant concentrations on the percent of 
entrapment efficiency, it was clear that decreasing the sur-
factant concentrations increased drug entrapment in the NPs 
(Figure 3). Although the percent of entrapment efficiency 
of batch 2 was slightly higher than batch 5, batch 5 was 
more stable over long-term (1 month) storage at 4°C (data 
not shown). The final composition was selected as shown in 
Table 3. Due to the enhanced solubility of drugs in the oil 
core, the newly developed formulation was capable of loading 
more DX conjugate (0.5–1 mg/mL conjugates vs 0.3 mg/mL 
DX) without significantly changing the physical properties 
of the resulting NPs. The optimal NPs had a mean particle 
size of 200 nm with a zeta potential around 0 mV (Table 3). 
The entrapment efficiencies of the three DX conjugates 
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Figure 1 synthesis of 2′-docetaxel conjugates.
Table 1 solubility of DX and DX conjugates in Miglyol 808 (N = 3)
Drug DX C12-DX C18-DX C22-DX
solubility in  
Miglyol 808 
(mg/mL)
52.1 ± 1.5 523.0 ± 18.2 550.5 ± 23.5 553.0 ± 21.0
Abbreviation: DX, docetaxel.
DX C12-DX C18-DX C22-DX
0
100
200
300
400
500
µ
g
/
m
L
Figure 2 solubility of DX conjugates in mouse plasma. 
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of large amounts of proteins and enzymes in the plasma. 
In our   developed “ex vivo” release method, NPs were spiked 
directly into 100% mouse plasma. Drug-containing NPs were 
separated from protein-bound DX conjugates and free DX 
conjugates using a Sepharose CL-4B column (GE Health-
care). The 15 cm, gravity-packed Sepharose CL-4B column 
was able to achieve baseline separation of the NPs with plasma 
proteins and free drugs, validated by dynamic light scattering 
intensity, BSA assay, and HPLC analysis (data not shown).
For the release studies, the DX conjugate-containing NPs 
were first purified by GPC and only NPs with size around 
200 nm (fraction 5–8) were collected. For all three DX 
conjugate NPs, an initial 45% burst release was observed 
upon spiking into the mouse plasma (Figure 4). After the 
initial burst release, C12-DX was slowly released to 86% 
in 8 hours, while no additional C18-DX and C22-DX were 
released from the NPs within 8 hours. A longer time point 
(96 hours) release study was carried out for the C18-DX 
NPs; however, no drug was released from the NPs after the 
burst (data not shown).
In vitro cytotoxicity
The cytotoxicity of DX conjugate NPs was studied in human 
prostate cancer DU-145 cells using the MTT assay (Figure 5). 
Both free DX conjugates and DX conjugate NPs showed a 
dose-dependent cytotoxicity in DU-145 cells. In general, 
all three DX conjugates had significantly lower cytotoxicity 
than unmodified DX in DU-145 cells. The decrease in cyto-
toxicity was chain-length dependent. As shown in Figure 5, 
free C12-DX was 20.6-fold less active than DX, and free 
C18-DX was 36.5-fold less active than DX. Free C22-DX 
was almost nontoxic to DU-145 cells. C12-DX and C18-DX 
NPs showed comparable IC50 values with their free forms, 
while C22-DX NPs showed similar toxicity to the blank NPs. 
The blank NPs IC50 was 1842 ± 287 nM in DX conjugate 
equivalent dose.
In vitro esterase digestion
The digestion rate of DX conjugates in mouse plasma 
bearing murine esterase activity was chain-length depen-
dent (Figure 6). C12-DX with the shortest fatty acid chain 
length disappeared in 8 hours, while about 80% and 90% of 
C18-DX and C22-DX were detected after 48 hours incuba-
tion, respectively.
In vivo pharmacokinetics
The plasma concentration-time curves in mice receiving 
intravenous bolus injections of Taxotere, C12-DX NPs, 
Table 2 Orthogonal design and responses
Run Brij 78 
(mg/mL)
TPGS 
(mg/mL)
Temperature  
(°C)
Entrapment  
(%)
Size 
(nm)
1 3.7 1.2 50 36.25 219.7
2 1.7 0.4 55 66.66 202.4
3 3.7 0.8 55 44.44 198.2
4 2.7 0.8 60 54.88 198.4
5 1.7 0.8 50 65.12 202.9
6 2.7 0.4 50 51.46 189.3
7 2.7 1.2 55 52.15 204.0
8 1.7 1.2 60 46.49 198.0
9 3.7 0.4 60 45.89 184.0
Notes:  Miglyol  808  concentration  was  2.5  mg/mL  for  all  9  runs.  c12-DX 
concentration was 0.5 mg/mL for all 9 runs. 
Abbreviations: TPgs, tocopheryl polyethylene glycol succinate; DX, docetaxel.
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Figure 3 3D surface plot for the modeling of the effect of Brij 78 and TPgs 
concentrations on percent of entrapment. 
Abbreviations: DX, docetaxel; TPgs, tocopheryl polyethylene glycol succinate.
were 55.2% ± 2.3%, 56.3% ± 7.6%, and 59.6% ± 1.6% for 
C12-DX, C18-DX, and C22-DX, respectively. The similar 
entrapment efficiencies of three DX conjugates was predicted 
by their comparable solubility in Miglyol 808 as shown in 
Table 1.
In vitro release of DX conjugates  
from NPs in mouse plasma
In this study, a novel in vitro release method was developed 
to study the release of DX conjugates from the NPs in 100% 
mouse plasma. The in vitro drug release of nano-  formulations 
is usually studied in aqueous buffer using a dialysis method. 
However, the correlation between in vitro release and 
in vivo pharmacokinetic profile is often poor due to the 
more complex in vivo environment, such as the presence International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Figure 4 release of DX conjugates from BTM NPs in mouse plasma. 
Abbreviations: DX, docetaxel; BTM, Brij 78, Vitamin e TPgs and Miglyol 808.
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Figure 5 In vitro cytotoxicity of free DX and DX conjugates and their NPs in 
DU-145 cells. 
Abbreviation: DX, docetaxel.
Table 3 compositions and properties of BTM 808 NPs
Miglyol 808  
(mg/mL)
Brij 78  
(mg/mL)
TPGS  
(mg/mL)
DX conjugate 
(mg/mL)
Temperature 
(°C)
Particle size  
(nm)
Zeta potential   
(mV)
2.5 1.7 0.8 0.5 55a 204.3 ± 8.9 -0.97 ± 0.08
Note: aTemperature was not a significant variable so average temperature of orthogonal design was utilized. 
Abbreviations: TPgs, tocopheryl polyethylene glycol succinate; DX, docetaxel.
C18-DX NPs, and C22-NPs at a dose of 10 mg DX/kg are 
shown in Figure 7A. Pharmacokinetic parameters obtained 
using a noncompartmental model of analysis are listed in 
Table 4A. The AUC0–∞ values of all NP-formulated DX 
conjugates were significantly higher than that of Taxotere. 
The AUCs increased as the conjugate chain length increased. 
The AUC0–∞ values of DX were 8.3-fold, 358-fold, and 454.5-
fold lower than that of NP-formulated C12-DX, C18-DX, 
and C22-DX, respectively. The terminal half-lives of NP-
formulated C18-DX and C22-DX were 1.9-fold and 3.4-fold 
longer than that of DX, respectively. The terminal half-life 
of NP-formulated C12-DX was shorter than that of DX. The 
volume of distribution of DX conjugates after administration 
of C12-DX NPs, C18-DX NPs, and C22-DX NPs were com-
parable. Overall, the volume of distribution of DX conjugate 
NPs was 20-fold lower than that of Taxotere.
The plasma concentrations of DX as an active metabo-
lite hydrolyzed from C12-DX, C18-DX, and C22-DX were 
determined and are shown in Figure 7B. DX concentrations of 
Taxotere are also shown as a reference for comparison. Phar-
macokinetic parameters of the noncompartmental model are 
shown in Table 4B. The plasma concentrations of DX from 
C22-DX NP were below the lower limit of   quantification. 
C12-DX NPs and C18-DX NPs improved DX AUC about 
3-fold compared to Taxotere. The AUC of DX from C12-DX 
NP was slightly higher than that of C18-DX NP and the 
Cmax of DX from C12-DX NPs was 16.7-fold higher than 
that of C18-DX NPs. However, the terminal half-life of DX 
from C18-DX NPs was 5-fold higher than that of C12-DX 
NPs. The DX from C12-DX NPs decreased promptly below 
the level of DX from C18-DX NPs 4 hours post-injection. 
Eight hours post-administration, the DX concentration from 
C12-DX NP decreased to the same level as Taxotere, whereas 
DX from C18-DX NP could be detected after 24 hours.
Discussion
In the present study, three DX-lipid conjugates, C12-DX, 
C18-DX, and C22-DX were synthesized and characterized. 
The solubility of all three DX-lipid conjugates in Miglyol 
808 was enhanced .10-fold over that of DX. Following opti-
mization of the DX conjugate NP using orthogonal design, 
the final optimized NPs contained significantly reduced 
surfactant concentrations and increased drug entrapment. The 
improved solubility of the DX conjugates in the NP liquid 
oil-phase led to very different pharmacokinetic profiles and 
blood exposure of DX.
A novel liquid oil-filled NP was previously developed in 
our laboratory, which was composed of Miglyol 812, Brij 78, 
and Vitamin E TPGS.25 During the initial development of NP to 
formulate DX, Miglyol 808 was selected over Miglyol 812 due International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 6 The digestion of free DX conjugates in fresh mouse plasma at 37°c. 
Note: Data are shown as mean ± sD (n = 3). 
Abbreviation: DX, docetaxel.
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Figure  7  Plasma  concentration-time  curves  for  (A)  DX,  c12-DX,  c18-DX, 
and c22-DX after administration of Taxotere, c12-DX NPs, c18-DX NPs, and 
c22-DX NPs, respectively, and (B) DX as an active metabolite from c12-DX NPs 
and c18-DX NPs using Taxotere as a reference. The plasma concentrations of DX 
from C22-DX NP were below the lower limit of quantification. 
Note: Data are shown as mean ± sD (n = 3). 
Abbreviation: DX, docetaxel.
to the significantly higher solubility of DX in Miglyol 808 
(52.07 ± 0.84 mg/mL) compared to that in Miglyol 812 
(36.11 ± 0.10 mg/mL, P , 0.01). The oil phase with higher 
drug solubility represents better compatibility and affinity of 
the drug with the inner liquid oil core of the delivery vehicles 
thereby leading to higher drug loading capacity and longer 
retention of drugs in the NPs. The high drug-loading capac-
ity minimizes the amount of the delivery vehicle needed to 
achieve the necessary drug dosage, thereby reducing the poten-
tial toxicity of the delivery vehicle. The .10-fold increase in 
the solubility of DX conjugates in Miglyol 808 compared to 
DX allowed for a significant increase in drug loading and 
entrapment. The comparable entrapment efficiency of the three 
DX conjugates in BTM 808 NPs was consistent with solubility 
of the conjugates in the Miglyol 808 liquid oil core.
While the solubility of DX conjugates in Miglyol 808 
strongly influenced the drug loading and entrapment effi-
ciency in the NP formulation, the partition of DX   conjugates 
in plasma was the driving force for their release in vivo. 
Results from the in vitro release studies showed that after 
an initial burst, an additional 40% of C12-DX having a 
relatively higher solubility in plasma was released from the 
NPs in 8 hours. In contrast, the C18-DX and C22-DX were 
extensively retained in the NPs after the initial burst release. 
It should be noted that all three DX-lipid conjugates showed 
an initial 45% burst release in mouse plasma using this “ex 
vivo” method, which suggests that the burst release was not 
related to the lipid chain length in this range. It is likely that 
the relatively more hydrophilic head group of the DX-lipid 
conjugates resided on the surface of NPs and promptly parti-
tioned to plasma proteins upon mixing with plasma. The burst 
release may not be a desirable property of NPs; however, it 
almost certainly reflects the true release behavior in vivo.
In vivo, NP-formulated C12-DX, C18-DX, and C22-DX 
achieved much higher AUCs compared to Taxotere, which 
was expected due to their better anchoring in the long-
circulating NPs. The low volume of distribution of DX 
conjugates was attributed to the size of NPs which limited 
their distribution to the normal tissues.26 The elimination 
routes and the relative contribution of each route for each 
conjugate varied. In addition to the elimination of conjugate 
containing NPs by the reticuloendothelial system (RES), the 
elimination of the conjugates was also attributed to two other 
possible mechanisms including release of the conjugate 
from the NPs and hydrolysis of the DX conjugates. The DX 
plasma concentration-time curves indicated that C12-DX 
was more quickly hydrolyzed to DX in vivo than the other 
two conjugates. C12-DX, with a shorter acyl chain, likely has International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 4B Pharmacokinetic parameters of DX after iv bolus administration of DX conjugates and Taxotere in mice
Taxotere C12-DX NP C18-DX NP C22-DX NP
t1/2 (hours) 3.63 1.09 5.42 –a
AUc0–24 (h*mg/L) 1.51 4.64 3.51
AUc0–∞ (h*mg/L) 1.55 4.66 3.66
Kel (1/hour) 0.19 0.63 0.13
cmax (mg/L) 7.21 12.31 0.74
MrT (hours) 0.87 0.89 6.98
Note: aBelow lower limit of quantification. 
Abbreviations: DX, docetaxel; AUc, area under the curve; MrT, mean retention time.
Table 4A Pharmacokinetic parameters of DX conjugates and Taxotere in mice after iv bolus administration
Taxotere C12-DX NP C18-DX NP C22-DX NP
t1/2 (hour) 3.63 0.99 6.80 12.44
AUc0–24 (h*mg/L) 1.51 12.78 508.63 505.56
AUc0–∞ (h*mg/L) 1.55 12.92 554.92 704.51
Vd (L/kg) 5.61 0.22 0.17 0.26
Kel (1/hour) 0.19 0.70 0.10 0.06
cL (L/hr/kg) 6.43 0.77 0.02 0.01
cmax (mg/L) 7.21 71.57 107.83 108.59
MrT (hour) 0.87 0.29 9.27 18.28
Abbreviations: DX, docetaxel; AUc, area under the curve; MrT, mean retention time.
less steric hindrance and is more readily cleaved to release 
DX. C12-DX in NPs was either released from the NPs fol-
lowed by hydrolysis to DX or was hydrolyzed to DX first, 
followed by quick release as DX. Regardless of the mecha-
nism, C12-DX had the shortest terminal half-life in vivo, 
which was even shorter than Taxotere. However, the plasma 
exposure of DX was the highest after C12-DX NP injec-
tion. In contrast, the longer acyl chain of C18-DX makes 
it less susceptible to hydrolysis and better anchored in 
the NPs in vivo resulting in a significant increase of the 
plasma exposure of the conjugate. As a result, the AUC of 
NP-formulated C18-DX was 43-fold higher than that of 
C12-DX. Because of the slower hydrolysis, the DX AUC 
from C18-DX NPs was lower compared to C12-DX NPs. 
However, as shown in Figure 7B, the duration of DX expo-
sure after C18-DX NP administration was much longer than 
C12-DX NPs. C18-DX NPs served as a drug reservoir and 
released DX in a sustained manner. It has been reported 
that prolonged time above a threshold concentration is 
ideal for cell cycle-specific drugs.27 Although DX was not 
detected after C22-DX NPs were injected into the blood, it 
is possible that the hydrolysis kinetics of C22-DX was too 
slow and the released DX was too quickly eliminated to be 
detected. It is worth noting that in the tumor site the overall 
anti-tumor toxicity comes from three forms: DX taken up by 
the tumors from the systemic circulation, the accumulating 
DX conjugates on their own, and the DX hydrolyzed from 
the accumulating conjugates in the site. It is possible that 
C22-DX is hydrolyzed to DX slowly after accumulating in 
the tumors.
While conjugating fatty acid chains to DX decreased its 
cell growth inhibitory activity in vitro, it may enhance the 
in vivo efficacy. Many studies have reported the reduction 
of PX or DX activity by conjugating fatty acid chains to 
2′-OH.21,23,24 This study is consistent with previous reports 
that in general, all three DX-lipid conjugates were less potent 
than DX against DU-145 cells, and increasing the lipid chain 
length decreased the cell growth inhibitory activity in vitro. 
It has been previously demonstrated that esterification at 
2′-OH or 7-OH abolished the microtubule binding affinity of 
the conjugates but not the total toxicity.28 The DX conjugates 
as ester prodrugs are expected to be cleaved to release free 
DX and exert their antitumor toxicity after cleavage. How-
ever, in the present 48 hours in vitro cytotoxicity study, the 
hydrolysis rate may not be fast enough to release all the DX. 
In addition, it is possible that DX conjugates as intact par-
ent drugs have alternative cytotoxic mechanisms other than 
microtubule binding. These additional mechanisms, if any, 
still remain to be investigated. The chain length-dependent 
cytotoxicity reduction may be explained by their different 
rate/extent of cellular uptake, different cellular compart-
mental sequester, and/or different rate/extent of hydrolysis/
degradation.   However, many studies have reported that 
in vivo efficacy does not necessarily correlate with in vitro International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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cytotoxicity. In a previous study,23 a series of PX prodrugs 
with various linkers and lipid anchors were synthesized. 
Among the lipophilic prodrugs of PX, the most potent com-
pound (compound 7) in vivo showed only moderate in vitro 
cytotoxicity. Another study showed that the 2′-(2-bromo)-
hexadecanoyl DX with lowest in vitro cytotoxicity in its kind 
was most effective in vivo, showing 100% survival at day 
300 for OVCAR-3-bearing SCID mice.24 The DHA-PX on 
clinical trial III prepared by linking PX to docosahexaenoic 
acid (DHA) was less toxic than PX in vitro but cured 10/10 
M109 tumor-bearing mice, whereas PX cured 0/10.29 Our 
pharmacokinetic results provided the basis for enhanced 
in vivo efficacy.
In conclusion, the NPs developed in these studies have 
low toxicity, long circulation in the blood, and released DX-
lipid conjugates in a slow and sustained manner in the plasma. 
Thus, the NPs have the potential to exert superior anti-tumor 
efficacy and less systemic toxicity in vivo. The results of these 
studies strongly support that the physical/chemical properties 
of DX conjugates may be fine-tuned to influence the affinity 
and retention of DX in oil-filled lipid NPs which therefore 
leads to very different pharmacokinetic profiles and blood 
exposure of DX. These studies demonstrate that the affinity 
of a drug for the core NP material may influence the reten-
tion and release rate of a drug from these NPs. In addition, 
a new “ex vivo” method was developed to better correlate 
and predict the release rate of a drug from a NP formulation 
to the resulting pharmacokinetic profile. These studies and 
methodologies may allow for improved and more potent 
nanoparticle-based formulations.
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